Sales Reps Will Make Case For Ranexa In First-Line Angina
This article was originally published in The Pink Sheet Daily
Executive Summary
New label, which exceeded CV Therapeutics’ expectations, highlights reduction of hemoglobin A1c levels and arrhythmias.